Question 1

What is a lyophilised peptide vial?

Accepted Answer

A vial of dry powder, freeze-dried so that it will keep, which is what lyophilised means. The compound is frozen and the water drawn off under vacuum, leaving a solid cake that occupies a fraction of the glass it sits in. Federal records describe the format constantly: a 2026 entry covers Tirzepatide, 60mg/10 mL for Injection, 10mL vial lyophilized, and a 2022 entry covers SERMORELIN ACETATE 6MG/IPAMORELIN 6MG - LYOPHILIZED 6MG/6MG VIAL. Drying is not a formality, and getting it wrong is a documented enforcement finding. A 2016 recall of a compounded sermorelin powder gives as its reason that it was not being compounded in an area appropriate for lyophilization which may lead to a lack of sterility assurance. So the dry cake is where the compound is stable enough to ship, and the liquid is where every question on this page begins.What happens after the syringe is filled belongs to the peptide injections overview instead.

Question 2

What do the labels that exist say about storing a vial?

Accepted Answer

Four words, repeated across the compounded injections in the federal record, and nothing more elaborate than that. A 2025 entry describes a compounded combination as Sterile, 2mL Multi Dose Vial, Refrigerate, Do not freeze. A 2022 entry for a different compounder carries the first of those instructions on its own, listing Semaglutide/Cyanocobalamin 5mg/0.2mg/ml, 2ml-vial, Refrigerate. Those instructions are regulatory facts about particular articles, printed by the firms that made them and held against them when something went wrong. What they are not is a general rule about peptides, and the distinction matters more here than almost anywhere else on this site. A storage instruction describes the formulation it was written for, at the concentration and in the container it was written for. A research-grade vial bought from an unlabelled source carries no such instruction, and it does not inherit one from a compounded product that happens to hold the same molecule.

Question 3

Do peptides need to be refrigerated?

Accepted Answer

Where a label exists, it says so, and where no label exists there is nothing to consult. A 2025 record for a compounded semaglutide combination reads Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, which is as explicit as these records get. That instruction was written for a sterile solution already made up by a pharmacy, not for a sealed cake of powder and not for a vial somebody mixed at home. The honest position is narrower than either answer circulating online. Among the sources behind this page, refrigeration appears as a manufacturer's instruction attached to specific finished articles, and not as a measured finding about peptides in general. Nothing we could find in this material reports an experiment holding one of these compounds at two temperatures and measuring what survived. So the fridge is what the labelled articles specify, and for everything else the honest answer is that the question has not been answered rather than that the answer is no.

Question 4

Are there peptides that are not supposed to be refrigerated?

Accepted Answer

Among the labels in this record, the prohibition is freezing rather than chilling. The compounded entries pair the two instructions in a single breath, as in Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze. Freezing is singled out because ice crystals disrupt a protein in solution, and because a frozen aqueous formulation can separate as it thaws. That is a well-established pharmaceutical concern rather than a peptide-specific one, and it applies to the made-up liquid rather than to the dry cake. The question is usually asked the other way round, as though some peptides were harmed by a refrigerator. No label among the records behind this page names chilling as a hazard for any of these compounds. What that establishes is the content of the instructions, not the behaviour of the molecules, and the two keep getting swapped for one another.

Question 5

What happens to a vial that is left out of the fridge?

Accepted Answer

Nobody covered by this material has measured it, and the work that sounds as though it answers the question is answering a different one. A 2026 analytical paper describes what made these compounds hard to find in urine. The obstacles it lists are their inherent in vivo instability, rapid renal clearance, and low urinary concentrations. A 2020 protein-engineering paper names rapid degradation by serum exopeptidases among the three problems it set out to solve. Read carefully, both of those describe instability inside a body. Enzymes in blood, filtration by a kidney, minutes and hours rather than weeks. Instability in circulation is not the same question as instability in a sealed vial on a kitchen counter. A peptide can be taken apart in plasma within minutes and still sit untouched as a dry solid for a year, because the two mechanisms are unrelated. That distinction is the most useful thing in this section, and it is why the confident shelf-life numbers online have nothing underneath them.

Question 6

How long does a vial last once it has been mixed?

Accepted Answer

The figure a reader is after is a beyond-use date, and for a labelled compounded preparation one demonstrably exists. A 2019 recall of a compounded tesamorelin powder was filed for exactly that: the vial indicates a 1 year expiration date instead of a 6 month expiration date. Two separate things are visible in that single line of enforcement text. The first is that a genuine dating interval existed for that preparation, and that the interval was six months rather than twelve. The second is that an incorrect date on a vial is consequential enough, by itself, to justify withdrawing an entire batch, which is a measure of the interpretive weight such a date carries. What no record among these sources supplies is a post-mixing interval for a research-grade vial, because a vial with no labeller has nobody to assign one. The related arithmetic is mechanical and this site will do it: how many millilitres a target amount works out at, and how many of those a vial holds, is handled at the calculators.

Question 7

Do peptides really go bad after 30 days?

Accepted Answer

Not from anything in this enforcement record, which is the most that can honestly be said about the figure. The concept the thirty days is reaching toward is genuine, and in compounding it carries a name: the beyond-use date, or BUD. It appears in the regulatory record as a documented deficiency rather than as a published interval. Two 2018 recalls of compounded hormone vials were filed because the Beyond Use Date (BUD) exceed the BUD/EXP of at least one ingredient used to make final product. That is a dating error with a particular shape: a finished preparation was assigned a life exceeding that of a constituent incorporated into it. It establishes that beyond-use dates are assigned, audited and enforced for compounded injections, and that they are derived from the constituents rather than from convention. No source among the research behind this page publishes a thirty-day interval for any compound indexed on this site. A figure with an accountable institution behind it and a figure circulating in a forum are categorically different objects, and only the former is verifiable.

Question 8

How would you tell whether a peptide has gone bad?

Accepted Answer

Not by looking at it, which is the part most worth saying plainly. Degradation is a change in the molecules themselves, and what finds it is a mass spectrometer. A 2023 doping-control method was validated according to WADA technical documents for selectivity, limit of detection (LOD), carryover, reliability of detection, stability and recovery. It was built to find these compounds at fractions of a nanogram per millilitre. That is the scale on which the question is actually settled. The commercial side is less settled than the analytical one. A 2026 evidence-mapping review of copper peptide formulations found that molar occupancy, labile copper, and release of intact GHK-Cu versus apo-GHK/free copper are usually not resolved in the delivery studies it examined. If published work often leaves the active species unresolved, a sealed vial from an unknown seller will not settle it either. The enforcement record contains the same gap in its bluntest form: a 2021 compounded hormone vial was withdrawn for CGMP deviations: Lack of potency testing.

Question 9

What is known about injecting a peptide that has degraded?

Accepted Answer

Very little, and the gap is specific enough to describe exactly. None of the studies covered here administers a deliberately aged or degraded vial to anything and then reports what followed. What the literature does describe is the fate of an intact peptide once it is inside, which is already short. A 2018 chemistry paper summarises the general problem, noting that these drugs are susceptible to enzymatic degradation, leading to their rapid elimination and thereby demanding frequent dosage. A degraded vial is a different situation again, because degradation produces fragments rather than nothing. Those fragments are other molecules, with their own behaviour, and whether they do anything at all is not a question this material has been asked. So the honest answer has two halves: the potency of an aged vial is unknown, and the identity of what replaced it is unknown as well. What is documented about adverse events for these compounds generally, intact or otherwise, is collected at the safety overview.

Question 10

Why are these molecules unstable in the first place?

Accepted Answer

Because a peptide is a short chain held together by bonds that living tissue is built to cut. A 2020 engineering paper puts the problem from the maker's side. It names three major problems of peptide drugs: instability in the expression host, rapid degradation by serum exopeptidases, and low bioactivity because of fast renal clearance. That is one problem in the factory and two in the body. A 2020 antiviral design paper hits the same wall at the bench, noting that their implementation is limited by low stability in biological media. The picture is not the same across the whole family, though, and that correction is worth having. A 2005 review of the glyproline peptides argues that the present concept of relative instability of regulatory peptides (RPs) in organisms must be amended. Some of them, it reports, keep about as well as ordinary drugs do. Fragility is therefore a property of one sequence rather than of the whole class. Nothing on this page generalises from one compound to another, and a storage claim borrowed from one vial does not travel to the next.

Question 11

Does the formulation matter more than the molecule?

Accepted Answer

Often it does, and the copper peptides show that most clearly. A 2026 review graded delivery studies against a fixed checklist rather than against their own claims. The matrix comprised formulation, claimed loading, molar copper occupancy, labile copper, species-resolved release, factorial controls, stability/manufacturability, and objective outcome. Read that list again and note where stability sits in it. It is one line among several, beside how much went in and how fast it comes back out. Stability is a property of the preparation, then, and not of the name on the label. Chemistry can move it outright as well. In a 2018 tripeptide study, glycoalkylated peptides did, however, show stability toward proteolytic enzymes. The plain sequence did not, and the only difference between the two was a sugar group added to one side chain. Same three building blocks, different keeping qualities. A label that names only the peptide inside has left out the thing that governs how long it holds.

Question 12

What are the common mistakes in peptide reconstitution?

Accepted Answer

The ones that reach a federal record are about the vial rather than about anybody's technique. Two keep recurring, and both are properties a reader can read off a label before any liquid is added. The first is what the vial contains besides the compound: a 2021 entry describes a compounded hormone product as Lyophilized, Unpreserved, meaning a powder with no preservative in it. An unpreserved container and a multidose one are a combination worth noticing, because the second implies repeated entry and the first supplies nothing to discourage growth between entries. The second is the unit the strength is written in. A 2020 record lists Lyophilized Human Chorionic Gonadotropin 5,500 USP Units For injection, which is a measure of biological activity rather than a mass in milligrams. A figure in units cannot be converted to milligrams by arithmetic, and assuming it can is the error that produces hundredfold results. The arithmetic itself, including the unit traps and the syringe markings, is worked through at the calculators.What the published amounts actually were, before any of that arithmetic is applied to them, is gathered on the dosing overview.

Question 13

What should not be mixed with a peptide?

Accepted Answer

One experiment in this material answers the question directly, and it is not about peptides sold to the public. A 2022 study incubated oxidised glutathione with the components of intravenous feeding solutions and measured what was left after 24 hours. The combination of cysteine and multivitamins caused the maximum loss of glutathione, and removing the cysteine prevented the degradation of glutathione. An amino acid already present in the bag destroyed most of the compound in a day, with no heat, no light and no contamination involved. That is the shape of the risk: a second ingredient can consume the first, quietly, in a sealed and sterile container. Compounded injections are sold as combinations all the time, and the records name them, as with Semaglutide +Cyanocobalamin 1.5 mg + 0.25mg/0.5 mL Inj Sol. Those combinations were formulated by a pharmacy against its own compatibility data, which is precisely what two vials combined by a buyer have none of. Interactions inside a person, as opposed to inside a vial, are a separate subject and are set out at the safety overview.

Question 14

How would you know the vial holds what the label says?

Accepted Answer

Not from anything in the box, and that is the limit this page runs into at every heading above. A 2026 critical review of peptide use in sport describes the supply directly, recording that the largely unregulated supply chain exacerbates these dangers, as products are often mislabeled or contaminated. Mislabelled and contaminated are two separate failures, and only one of them is about the compound anybody meant to buy. Identifying these molecules is difficult even with instruments, as the same review notes: analytical challenges remain due to peptides' structural similarity to endogenous hormones and short half-lives. If an accredited doping laboratory finds the identification demanding, a home test strip is not going to settle it. What can be checked is the paperwork rather than the powder: which batch a certificate covers, who ran the assay, and what the method was. How to read one of those documents, and what it does and does not cover, is laid out at the sourcing overview.

Using Peptides: Vials, Storage and Shelf Life